FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886256490> ?p ?o ?g. }

• W2886256490 abstract "Melanoma is one of the most lethal forms of skin cancer that kills an average of around one person every hour in the United States alone. Melanoma can be surgically removed if diagnosed early, however, undiagnosed or untreated melanomas can rapidly metastasize to become lethal. Significant progress has been made in the treatment of metastatic melanoma over the past decade, especially with novel targeted therapeutic approaches (such as BRAF- and MEK- inhibitors or immunotherapies). However, even with these newer therapies, melanoma can acquire resistance and become untreatable, with fatal consequences. Therefore, novel therapeutic approaches are required for the management of this neoplasm. It is commonly accepted that mechanism-based combination therapeutics could be better for an efficient and complete elimination of cancer cells, thereby limiting the chances of recurrence and resistance. Based on this rationale, we reasoned that a simultaneous targeting of G2/M and G1 phases of the cell cycle could provide a more efficacious response against melanoma. Studies in our laboratory have suggested that polo-like kinase 1 (PLK1), which is a mitotic regulator acting in the G2/M phase of the cell cycle, is overexpressed in melanoma and is a potentially druggable target for melanoma management. We demonstrated that BI6727, a small-molecule PLK1 inhibitor, resulted in delay and regression of melanoma xenografts. Similarly, dysregulation of the p16-cyclin D1-CDK4/6-Rb pathway has been shown to frequently occur in melanoma, and CDK4/6 inhibition is being extensively investigated in the management of several cancers, including melanoma. In this study, we evaluated the anti-proliferative efficacy of a combination of G2/M-phase targeting by BI6727 and G1-phase targeting by the CDK4/6 inhibitor LY2835219 in human melanoma cells. We determined the effect of BI6727 and/or LY2835219 on growth and viability of human melanoma cells using the RealTime-Glo Cell Viability- and Trypan Blue exclusion- assays. We found that the combination of BI6727 and LY2835219 resulted in a better anti-proliferative response, when compared to either of the agents alone. Further, the combination treatment was found to result in a marked decrease in the clonogenic survival of melanoma cells, as assessed by colony formation assay. Cell cycle analysis showed a G2/M-phase arrest in BI6727 treated cells and G1-phase arrest in LY2835219 treated cells. Interestingly, the combination was found to cause G2/M as well as G1- phase arrest of melanoma cells. Overall, our data suggests that a concomitant inhibition of PLK1 with CDK4/6 provides a superior anti-proliferative response, suggesting that dual inhibition should be further evaluated in detailed in vitro and in vivo experiments. Additional studies to determine the mechanisms of this combination are currently underway in our laboratory. Citation Format: Sanghamitra Nethramurthy, Mary A. Ndiaye, Chandra K. Singh, Nihal Ahmad. Combination of volasertib (BI6727) and abemaciclib (LY2835219) for melanoma management: Concomitant targeting of multiple cell cycle phases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5830." @default.
• W2886256490 created "2018-08-22" @default.
• W2886256490 creator A5025592530 @default.
• W2886256490 creator A5044445781 @default.
• W2886256490 creator A5045348217 @default.
• W2886256490 creator A5051028478 @default.
• W2886256490 date "2018-07-01" @default.
• W2886256490 modified "2023-09-25" @default.
• W2886256490 title "Abstract 5830: Combination of volasertib (BI6727) and abemaciclib (LY2835219) for melanoma management: Concomitant targeting of multiple cell cycle phases" @default.
• W2886256490 doi "https://doi.org/10.1158/1538-7445.am2018-5830" @default.
• W2886256490 hasPublicationYear "2018" @default.
• W2886256490 type Work @default.
• W2886256490 sameAs 2886256490 @default.
• W2886256490 citedByCount "0" @default.
• W2886256490 crossrefType "proceedings-article" @default.
• W2886256490 hasAuthorship W2886256490A5025592530 @default.
• W2886256490 hasAuthorship W2886256490A5044445781 @default.
• W2886256490 hasAuthorship W2886256490A5045348217 @default.
• W2886256490 hasAuthorship W2886256490A5051028478 @default.
• W2886256490 hasConcept C121608353 @default.
• W2886256490 hasConcept C126322002 @default.
• W2886256490 hasConcept C143998085 @default.
• W2886256490 hasConcept C2775930923 @default.
• W2886256490 hasConcept C2776131300 @default.
• W2886256490 hasConcept C2777658100 @default.
• W2886256490 hasConcept C2779744173 @default.
• W2886256490 hasConcept C2781230642 @default.
• W2886256490 hasConcept C29537977 @default.
• W2886256490 hasConcept C2994587330 @default.
• W2886256490 hasConcept C502942594 @default.
• W2886256490 hasConcept C530470458 @default.
• W2886256490 hasConcept C71924100 @default.
• W2886256490 hasConceptScore W2886256490C121608353 @default.
• W2886256490 hasConceptScore W2886256490C126322002 @default.
• W2886256490 hasConceptScore W2886256490C143998085 @default.
• W2886256490 hasConceptScore W2886256490C2775930923 @default.
• W2886256490 hasConceptScore W2886256490C2776131300 @default.
• W2886256490 hasConceptScore W2886256490C2777658100 @default.
• W2886256490 hasConceptScore W2886256490C2779744173 @default.
• W2886256490 hasConceptScore W2886256490C2781230642 @default.
• W2886256490 hasConceptScore W2886256490C29537977 @default.
• W2886256490 hasConceptScore W2886256490C2994587330 @default.
• W2886256490 hasConceptScore W2886256490C502942594 @default.
• W2886256490 hasConceptScore W2886256490C530470458 @default.
• W2886256490 hasConceptScore W2886256490C71924100 @default.
• W2886256490 hasLocation W28862564901 @default.
• W2886256490 hasOpenAccess W2886256490 @default.
• W2886256490 hasPrimaryLocation W28862564901 @default.
• W2886256490 hasRelatedWork W1510276410 @default.
• W2886256490 hasRelatedWork W1545829378 @default.
• W2886256490 hasRelatedWork W1875726064 @default.
• W2886256490 hasRelatedWork W1921841920 @default.
• W2886256490 hasRelatedWork W2239758289 @default.
• W2886256490 hasRelatedWork W2808608845 @default.
• W2886256490 hasRelatedWork W2886256490 @default.
• W2886256490 hasRelatedWork W2887451076 @default.
• W2886256490 hasRelatedWork W3023401146 @default.
• W2886256490 hasRelatedWork W4220929959 @default.
• W2886256490 isParatext "false" @default.
• W2886256490 isRetracted "false" @default.
• W2886256490 magId "2886256490" @default.
• W2886256490 workType "article" @default.